Intrinsic Fibrinolysis and Arterial Thrombosis

Vascular and Endovascular Surgery

Volumn 34, Issue 3, 2000, Pages 193-199

  Killewich, Lois A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; EXERCISE; FIBRINOLYSIS; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NOTE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; STROKE; THROMBOSIS;

EID: 0034028223     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/153857440003400302     Document Type: Article

References (55)

1. Rao AK, Sheth S, Kaplan R: Inherited hypercoagulable states. Vasc Med 2: 313-320, 1997.
2. Denys J, De Marbaix H: Les peptonisations provoquees par le chloroforme. Cellule 5: 197-197, 1889.
3. Dastre A: Fibrinolyse dans le sang. Arch Norm Pathol 5: 661-664, 1893.
4. Verstraete M: The fibrinolytic system: From Petri dishes to genetic engineering. Thromb Haemost 74: 25-35, 1995.
5. Preissner KT, Kanse SM, Chavakis T, et al: The dual role of the urokinase receptor system in pericellular proteolysis and cell adhesion: Implications for cardiovascular function. Basic Res Cardiol 94: 315-321, 1999.
6. Kannel WB, D'Agostino RB, Belanger AJ, et al: Longterm influence of fibrinogen on initial and recurrent cardiovascular events in men and women. Am J Cardiol 78: 90-92, 1996.
7. Kannel WB: Influence of fibrinogen on cardiovascular disease. Drugs 54(suppl 3):32-40, 1997.
8. Ernst E, Resch KL: Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 118: 956-963, 1993.
9. de la Serna G: Fibrinogen: A new major risk factor for cardiovascular disease. A review of the literature. J Fam Pract 39: 468-477, 1994.
10. Bolibar I, Kienast J, Thompson MA, et al: ECAT Angina Pectoris Study Group. Relation of fibrinogen to presence and severity of coronary artery disease is independent of other coexisting heart disease. Am Heart J 125: 1601-1605, 1993.
11. Handa K, Kono S. Saku K, et al: Plasma fibrinogen level as an indicator of severity of coronary atherosclerosis. Atherosclerosis 77: 209-213, 1989.
12. Hamsten A, de Faire U. Walldius G, et al: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2: 3-9, 1987.
13. Juhan-Vague I, Pyke SDM, Alessi MC, et al: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 94: 2057-2063, 1996.
14. Gray RP, Yudkin JS, Patterson DLH: Plasminogen activator inhibitor: A risk factor for myocardial infarction in diabetic subjects. Br Heart J 69: 228-232, 1993.
15. Gray RP, Patterson DL, Yudkin JS: Plasminogen activator inhibitor activity in diabetic and non-diabetic survivors of myocardial infarction. Arterioscler Thromb 13: 415-420, 1993.
16. Thompson SG, Kienast J, Pyke SDM, et al: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332: 635-641, 1995.
17. Ranby M, N'Guyen G, Scarabin PY, et al: Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Thromb Haemost 61: 409-414, 1989.
18. Chandler WL, Alessi MC, Aillaud MF, et al: Clearance of tissue plasminogen activator (tPA) and tPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Relationship to elevated tPA antigen in patients with high PAI-1 activity levels. Circulation 96: 761-768, 1997.
19. Fuster V, Verstraete M (eds): Thrombosis in Cardiovascular Disorders. Philadelphia: WB Saunders, 1992, pp 55-61.
20. Ducimetiere P. Eschwege E, Papoz L, et al: Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 19: 205-210, 1980.
21. Despres J-P, Lamarche B, Mauriege P, et al: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334: 952-957, 1996.
22. Yudkin JS: Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 22(suppl 3):C25-C29, 1999.
23. Juhan-Vague I, Roul C, Alessi C, et al: Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic subjects: Relationship with plasma insulin. Thromb Haemost 61: 370-373, 1989.
24. Potter van Loon BJ, Kluft C, Radder JK, et al: The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42: 945-949, 1993.
25. Landin K, Tengborn L, Smith U: Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227: 273-278, 1990.
26. Juhan-Vague I, Thompson SG, Jespersen J: Involvement of the hemostatic system in the insulin resistance syndrome: A study of 1,500 patients with angina pectoris. Arterioscler Thromb 13: 1865-1873, 1993.
27. Dawson SJ, Wiman B, Hamsten A, et al: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268: 10739-10745, 1993.
28. Eriksson P, Kallin B, van't Hooft FM, et al: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92: 1851-1855, 1995.
29. Panahloo A, Mohamed-Ali V, Lane A, et al: Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 44: 37-42, 1995.
30. Ye S, Green FR, Scarabin PY, et al: The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-i (PAI-1) gene is associated with ECTIM study. Thromb Haemost 74: 837-841, 1995.
31. Gardemann A, Lohre J, Katz N, et al: The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 82: 1121-1126, 1999.
32. Mansfield MW, Stickland JH, Grant PJ: Plasminogen activator-i (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 74: 1032-1034, 1995.
33. Ridker PM, Hennekens CH, Lindpaintner K, et al: Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 95: 59-62, 1997.
34. Burzotta F. Di Castelnuovo A, Amore C, et al: 4G/5G polymorphism in the promoter region of the PAI-I gene is not a risk factor for familial myocardial infarction: A case-control study in a sample of GISSI-2 patients. Thromb Haemost 78: 1294-1295, 1997.
35. lacoviello L, Burzotta F, De Castelnuovo A, et al: The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A meta-analysis. Thromb Haemost 80: 1029-1030, 1998.
36. Humphries SE, Cook M, Dubowitz M, et al: Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1: 1452-1455, 1987.
37. Berg K, Kierulf P: DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentration. Clin Genet 36: 229-235, 1989.
38. de Maat MPM, Kastelein JJP, Jukema JW, et al: -455G/A polymorphism of the,B-fibrinogen gene is associated with the progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 18: 265-271, 1998.
39. Paramo JA, Olavide I, Barba J, et al: Long-term cardiac rehabilitation program favorably influences fibrinolysis and lipid concentrations in acute myocardial infarction. Haematologica 83: 519-524, 1998.
40. Lee AJ, Fowkes FGR, Lowe GDO, et al: Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh artery study. Thromb Haemost 81: 553-560, 1999.
41. Kannel WB, D'Agostino RB, Belanger AJ: Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 2: 457-466, 1992.
42. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, et al: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311: 501-505, 1984.
43. Smith FB, Lee AJ, Fowkes FG, et al: Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh artery study. Arterioscler Thromb Vasc Biol 17: 3321-3325, 1997.
44. Carter AM, Catto AJ, Grant PJ: Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease. Thromb Haemost 80: 632-636, 1998.
45. Mansfield MW, Catto AJ, Carter AM, et al: Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction. Diabet Med 15: 953-957, 1998.
46. Macko RF, Kittner SJ, Epstein A, et al: Elevated tissue plasminogen activator antigen and stroke risk. The stroke prevention in young women study. Stroke 30: 7-11, 1999.
47. Killewich LA, Macko RF, Gardner AW, et al: Defective fibrinolysis occurs after infrainguinal reconstruction. J Vasc Surg 25: 858-865, 1997.
48. Killewich LA, Gardner AW, Macko RF, et al: Progressive intermittent claudication is associated with impaired fibrinolysis. J Vasc Surg 27: 645-650, 1998.
49. Stratton JR, Chandler WL, Schwartz RS, et al: Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. Circulation 83: 1692-1697, 1991.
50. Lindahl B, Nilsson TK, Jansson JH, et al: Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance. J Intern Med 246: 105-112, 1999.
51. Dunstan DW, Mori TA, Puddey IA, et al: A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics. Thromb Haemost 81: 367-372, 1999.
52. Cahan MA, Killewich LA, Gardner AW: Enhancement of fibrinolysis in peripheral arterial occlusive disease with physical activity: A mechanism for reduction of cardiovascular events. Abstract at Society for Vascular Medicine and Biology Annual Meeting, June 2-3,1999, Washington, D.C.
53. Killewich LA, Macko RF, Wiley LA, et al: Exercise enhances endogenous fibrinolysis in peripheral arterial occlusive disease. Circulation, submitted for publication.
54. Hakim AA, Petrovitch H, Burchfiel CM, et al: Effects of walking on mortality among nonsmoking retired men. N Engl J Med 338: 94-99, 1998.
55. Friederich PW, Levi M, Biemond BJ, et al: Novel lowmolecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation 96: 916-921, 1997.